Cargando…

Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions

A vaccine breakthrough infection and a rebound infection cases of COVID-19 are studied and analyzed for the ten U.S. Department of Health and Human Services (HHS) regions and the United States as a nation in this work. An innovative multi-strain susceptible-vaccinated-exposed-asymptomatic-symptomati...

Descripción completa

Detalles Bibliográficos
Autores principales: Otunuga, Olusegun Michael, Yu, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234841/
https://www.ncbi.nlm.nih.gov/pubmed/37361410
http://dx.doi.org/10.1016/j.idm.2023.05.010
_version_ 1785052587874058240
author Otunuga, Olusegun Michael
Yu, Alexandra
author_facet Otunuga, Olusegun Michael
Yu, Alexandra
author_sort Otunuga, Olusegun Michael
collection PubMed
description A vaccine breakthrough infection and a rebound infection cases of COVID-19 are studied and analyzed for the ten U.S. Department of Health and Human Services (HHS) regions and the United States as a nation in this work. An innovative multi-strain susceptible-vaccinated-exposed-asymptomatic-symptomatic-recovered (SVEAIR) epidemic model is developed for this purpose for a population assumed to be susceptible to n-different variants of the disease, and those who are vaccinated and recovered from a specific strain k(k ≤ n) of the disease are immune to present strain and its predecessors j = 1, 2, …, k, but can still be infected by newer emerging strains j = k + 1, k + 2, …, n. The model is used to estimate epidemiological parameters, namely, the latent and infectious periods, the transmission rates, vaccination rates, recovery rates for each of the Delta B.1.617.2, Omicron B.1.1.529, and lineages BA.2, BA.2.12.1, BA.4, BA.5, BA.1.1, BA.4.6, and BA.5.2.6 for the United States and for each of the ten HHS regions. The transmission rate is estimated for both the asymptomatic and symptomatic cases. The effect of vaccines on each strain is analyzed. Condition that guarantees existence of an endemic with certain number of strains is derived and used to describe the endemic state of the population.
format Online
Article
Text
id pubmed-10234841
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-102348412023-06-02 Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions Otunuga, Olusegun Michael Yu, Alexandra Infect Dis Model Article A vaccine breakthrough infection and a rebound infection cases of COVID-19 are studied and analyzed for the ten U.S. Department of Health and Human Services (HHS) regions and the United States as a nation in this work. An innovative multi-strain susceptible-vaccinated-exposed-asymptomatic-symptomatic-recovered (SVEAIR) epidemic model is developed for this purpose for a population assumed to be susceptible to n-different variants of the disease, and those who are vaccinated and recovered from a specific strain k(k ≤ n) of the disease are immune to present strain and its predecessors j = 1, 2, …, k, but can still be infected by newer emerging strains j = k + 1, k + 2, …, n. The model is used to estimate epidemiological parameters, namely, the latent and infectious periods, the transmission rates, vaccination rates, recovery rates for each of the Delta B.1.617.2, Omicron B.1.1.529, and lineages BA.2, BA.2.12.1, BA.4, BA.5, BA.1.1, BA.4.6, and BA.5.2.6 for the United States and for each of the ten HHS regions. The transmission rate is estimated for both the asymptomatic and symptomatic cases. The effect of vaccines on each strain is analyzed. Condition that guarantees existence of an endemic with certain number of strains is derived and used to describe the endemic state of the population. KeAi Publishing 2023-06-02 /pmc/articles/PMC10234841/ /pubmed/37361410 http://dx.doi.org/10.1016/j.idm.2023.05.010 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Otunuga, Olusegun Michael
Yu, Alexandra
Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions
title Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions
title_full Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions
title_fullStr Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions
title_full_unstemmed Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions
title_short Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions
title_sort vaccine breakthrough and rebound infections modeling: analysis for the united states and the ten u.s. hhs regions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234841/
https://www.ncbi.nlm.nih.gov/pubmed/37361410
http://dx.doi.org/10.1016/j.idm.2023.05.010
work_keys_str_mv AT otunugaolusegunmichael vaccinebreakthroughandreboundinfectionsmodelinganalysisfortheunitedstatesandthetenushhsregions
AT yualexandra vaccinebreakthroughandreboundinfectionsmodelinganalysisfortheunitedstatesandthetenushhsregions